FUSN Stock Price, Fusion Pharmaceuticals Quote, Chart

Market Summary

USD21.50+0.04

Delayed

0.19%

FUSN Stock Price

View Fullscreen

FUSN RSI Chart

FUSN Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-17.54

Price/Sales (Trailing)

164.56

EV/EBITDA

-21.13

Price/Free Cashflow

-20.86

FUSN Price/Sales (Trailing)

FUSN Profitability

EBT Margin

-846.85%

Return on Equity

-43.12%

Return on Assets

-32.2%

Free Cashflow Yield

-4.79%

FUSN Fundamentals

FUSN Revenue

Revenue (TTM)

11.1M

Rev. Growth (Yr)

82.61%

Rev. Growth (Qtr)

53.05%

FUSN Earnings

Earnings (TTM)

-104.3M

Earnings Growth (Yr)

-38.61%

Earnings Growth (Qtr)

-19.49%

Breaking Down FUSN Revenue

Last 7 days

0.1%

Last 30 days

1.2%

Last 90 days

77.3%

Trailing 12 Months

405.9%

How does FUSN drawdown profile look like?

FUSN Financial Health

Current Ratio

10.64

Debt/Equity

0.21

Debt/Cashflow

-1.68

FUSN Investor Care

Shares Dilution (1Y)

33.23%

Diluted EPS (TTM)

-1.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	11.1M	0	0	0
2023	4.0M	6.3M	8.5M	9.5M
2022	826.0K	1.3M	1.7M	2.2M
2021	0	0	0	381.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Fusion Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 31, 2023	rawat mohit	acquired	-	-	12,843	president & cbo
Aug 31, 2023	leamon christopher p	acquired	-	-	11,957	chief scientific officer
Nov 11, 2022	khuong chau quang	acquired	100,181	2.38	42,093	-
Aug 11, 2022	gannon steven	bought	90,132	2.03	44,400	-
Apr 27, 2022	valliant john	sold	-27,201	6.03	-4,511	chief executive officer
Apr 26, 2022	valliant john	sold	-13,032	6.07	-2,147	chief executive officer
Apr 25, 2022	valliant john	sold	-12,277	6.03	-2,036	chief executive officer
Apr 21, 2022	valliant john	sold	-5,541	6.01	-922	chief executive officer
Apr 20, 2022	valliant john	sold	-2,209	6.02	-367	chief executive officer
Apr 13, 2022	valliant john	sold	-76,881	6.41	-11,994	chief executive officer

Which funds bought or sold FUSN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Artal Group S.A.	sold off	-100	-9,663,000	-	-%
May 17, 2024	Ikarian Capital, LLC	sold off	-100	-4,805,000	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	new	-	832,354	832,354	-%
May 16, 2024	JANE STREET GROUP, LLC	added	2,153	13,245,100	13,515,400	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	sold off	-100	-1,477,940	-	-%
May 15, 2024	PERCEPTIVE ADVISORS LLC	added	148	119,077,000	145,517,000	2.53%
May 15, 2024	Centiva Capital, LP	new	-	746,200	746,200	0.02%
May 15, 2024	Hudson Bay Capital Management LP	new	-	3,517,800	3,517,800	0.02%
May 15, 2024	GTS SECURITIES LLC	new	-	620,305	620,305	-%
May 15, 2024	Pentwater Capital Management LP	new	-	80,627,500	80,627,500	0.83%

Are Funds Buying or Selling FUSN?

Are funds buying FUSN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FUSN

No. of Funds

Unveiling Fusion Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 08, 2024	federated hermes, inc.	11%	95,000	SC 13G/A
Mar 25, 2024	federated hermes, inc.	12.65%	10,716,153	SC 13D
Mar 20, 2024	healthcap vii, l.p.	4.5%	3,807,247	SC 13D/A
Mar 07, 2024	healthcap vii, l.p.	5.3%	3,807,247	SC 13D/A
Feb 14, 2024	canada pension plan investment board	4.%	3,116,966	SC 13G/A
Feb 13, 2024	avidity partners management lp	8.1%	6,500,328	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 19, 2024	perceptive advisors llc	6.5%	4,737,194	SC 13G
Jan 18, 2024	federated hermes, inc.	15.03%	10,886,153	SC 13G/A
Dec 18, 2023	flynn james e	8.84%	6,401,000	SC 13G

Recent SEC filings of Fusion Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 10, 2024	8-K	Current Report
May 10, 2024	DEFA14A	DEFA14A
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
May 02, 2024	8-K	Current Report
May 02, 2024	DEFA14A	DEFA14A
Apr 25, 2024	DEFM14A	DEFM14A
Apr 23, 2024	8-K	Current Report
Apr 23, 2024	DEFA14A	DEFA14A
Apr 12, 2024	10-K/A	Annual Report

Peers (Alternatives to Fusion Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Fusion Pharmaceuticals Inc News

Latest updates

Fusion Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Revenue	53.1%	3,508,000	2,292,000	2,818,000	2,495,000	1,921,000	1,308,000	572,000	198,000	83,000	204,000	325,000	521,000
Operating Expenses	26.8%	35,860,000	28,275,000	21,395,000	26,747,000	24,883,000	24,557,000	23,971,000	19,857,000	21,110,000	18,147,000	19,840,000	27,788,000
S&GA Expenses	-100.0%	-	7,628,000	6,810,000	7,753,000	9,006,000	6,950,000	7,420,000	7,781,000	8,449,000	6,336,000	7,156,000	6,642,000
R&D Expenses	3.2%	21,312,000	20,647,000	14,585,000	18,994,000	15,877,000	17,607,000	16,551,000	12,076,000	12,661,000	11,811,000	12,684,000	21,146,000
EBITDA Margin	14.9%	-7.88	-9.25	-9.78	-13.45	-21.51	-40.31	-47.06	-59.40	-99.88	-210	-	-
Interest Expenses	36.7%	1,629,000	1,192,000	1,186,000	1,150,000	1,096,000	1,203,500	190,000	-53,000	83,000	81,000	107,000	97,000
Income Taxes	-118.3%	-237,000	1,297,000	-300,000	-200,000	-11,000	-329,000	-761,000	-700,000	-55,000	-173,000	48,000	14,000
Earnings Before Taxes	-	-	-	-	-	-	-24,957,000	-24,774,000	-19,754,000	-19,964,000	-17,409,000	-19,381,000	-26,839,000
EBT Margin	14.3%	-8.47	-9.88	-10.47	-14.21	-22.37	-41.39	-47.73	-60.20	-101	-213	-	-
Net Income	-19.5%	-33,670,000	-28,179,000	-17,252,000	-25,175,000	-24,291,000	-24,617,000	-24,013,000	-19,073,000	-19,909,000	-17,236,000	-19,429,000	-26,853,000
Net Income Margin	5.8%	-9.38	-9.96	-10.69	-15.58	-23.00	-40.54	-46.75	-59.52	-101	-212	-	-
Free Cashflow	-47.4%	-28,640,000	-19,428,000	-19,312,000	-20,294,000	-26,658,000	-20,314,000	-21,847,000	-17,691,000	-15,566,000	-16,865,000	-21,670,000	-17,516,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	13.3%	324	286	253	268	267	219	238	228	236	252	268	282	297	311	312	323	69.00
Current Assets	-9.2%	221	243	203	208	221	179	216	207	205	212	203	185	234	228	297	320	67.00
Cash Equivalents	-52.6%	29.00	61.00	27.00	32.00	54.00	44.00	107	63.00	61.00	55.00	40.00	30.00	43.00	92.00	251	321	67.00
Net PPE	24.1%	7.00	5.00	5.00	6.00	5.00	5.00	4.00	4.00	3.00	3.00	2.00	3.00	3.00	2.00	2.00	1.00	1.00
Liabilities	29.4%	82.00	63.00	65.00	65.00	66.00	57.00	55.00	29.00	21.00	21.00	22.00	19.00	18.00	16.00	6.00	8.00	10.00
Current Liabilities	28.0%	21.00	16.00	17.00	17.00	17.00	15.00	13.00	12.00	12.00	13.00	14.00	9.00	8.00	12.00	5.00	8.00	4.00
Long Term Debt	42.9%	50.00	35.00	35.00	34.00	34.00	34.00	34.00	10.00	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	35.00	35.00	34.00	34.00	34.00	34.00	10.00	-	-	-	-	-	-	-	-	-
Shareholder's Equity	8.7%	242	222	188	203	201	162	183	199	215	231	246	264	279	295	306	315	-
Retained Earnings	-8.9%	-410	-376	-348	-331	-306	-281	-257	-233	-214	-194	-177	-157	-130	-113	-99.82	-89.82	-34.77
Additional Paid-In Capital	9.0%	653	599	538	535	507	445	442	433	430	426	423	421	410	408	406	405	1.00
Shares Outstanding	6.5%	85.00	80.00	69.00	69.00	63.00	45.00	44.00	43.00	43.00	43.00	43.00	43.00	-	-	-	-	-
Float	-	-	-	-	302	-	-	-	98.00	-	-	-	274	-	-	-	545	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	-52.2%	-27,306	-17,944	-18,839	-19,584	-25,435	-19,364	-21,625	-17,316	-14,971	-16,327	-21,510	-17,307	-20,596	-3,082	-12,868	-6,197	-7,620	-	-	-
Share Based Compensation	38.8%	4,517	3,255	2,994	3,046	3,149	2,778	2,697	2,736	2,633	2,366	2,374	2,145	1,718	1,343	1,241	426	358	-	-	-
Cashflow From Investing	-1242.4%	-70,371	-5,242	13,326	-26,319	-24,528	-42,933	37,248	9,641	19,131	30,896	32,217	3,659	-28,998	-155,104	-54,967	-168	-214	-	-	-
Cashflow From Financing	10.6%	64,011	57,855	328	24,308	59,515	131	28,905	9,988	1,709	-50.00	57.00	210	130	56.00	-2,296	257,840	9,907	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

FUSN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Total revenue		$ 28
Type of Revenue [Extensible List]	us-gaap:CollaborativeArrangementMember	us-gaap:CollaborativeArrangementMember
Operating expenses:
Research and development	$ 21,312	$ 15,877
General and administrative	14,548	9,006
Total operating expenses	35,860	24,883
Loss from operations	(35,860)	(24,855)
Other income (expense):
Interest income	3,508	1,921
Interest expense	(1,852)	(1,223)
Other income (expense), net	297	(145)
Total other income (expense), net	1,953	553
Loss before benefit for income taxes	(33,907)	(24,302)
Income tax benefit	237	11
Net loss	(33,670)	(24,291)
Unrealized (loss) gain on investments	(819)	384
Comprehensive loss	$ (34,489)	$ (23,907)
Net loss per share -basic	$ (0.4)	$ (0.45)
Net loss per share -diluted	$ (0.4)	$ (0.45)
Weighted-average common shares outstanding-basic	83,775,652	53,775,985
Weighted-average common shares outstanding-diluted	83,775,652	53,775,985

FUSN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 27,790	$ 61,456
Accounts receivable		7
Short-term investments	182,735	172,153
Prepaid expenses and other current assets	9,923	9,310
Restricted cash	469	469
Total current assets	220,917	243,395
Property and equipment, net	6,584	5,304
Deferred tax assets	4,366	3,961
Restricted cash	849	849
Long-term investments	72,585	13,735
Operating lease right-of-use assets	17,861	18,592
Other non-current assets	652
Total assets	323,814	285,836
Current liabilities:
Accounts payable	2,503	1,860
Accrued expenses and other current liabilities	13,632	9,864
Deferred revenue	333	333
Operating lease liabilities	4,288	4,163
Total current liabilities	20,756	16,220
Long-term debt, net of discount	49,686	34,775
Income taxes payable, net of current portion	301	301
Deferred revenue, net of current portion	667	667
Operating lease liabilities, net of current portion	10,573	11,393
Total liabilities	81,983	63,356
Commitments and contingencies (Note 15)
Shareholders’ equity:
Common shares, no par value, unlimited shares authorized as of March 31, 2024 and December 31, 2023; 84,865,021 and 79,700,262 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively
Additional paid-in capital	652,842	599,002
Accumulated other comprehensive (loss) income	(582)	237
Accumulated deficit	(410,429)	(376,759)
Total shareholders' equity	241,831	222,480
Total liabilities and shareholders’ equity	$ 323,814	$ 285,836

About Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

CEO	Dr. John F. Valliant Ph.D.
WEBSITE	https://fusionpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	101

Fusion Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Fusion Pharmaceuticals Inc? What does FUSN stand for in stocks?

FUSN is the stock ticker symbol of Fusion Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fusion Pharmaceuticals Inc (FUSN)?

As of Fri May 17 2024, market cap of Fusion Pharmaceuticals Inc is 1.83 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FUSN stock?

You can check FUSN's fair value in chart for subscribers.

What is the fair value of FUSN stock?

You can check FUSN's fair value in chart for subscribers. The fair value of Fusion Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Fusion Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FUSN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Fusion Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether FUSN is over valued or under valued. Whether Fusion Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Fusion Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FUSN.

What is Fusion Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, FUSN's PE ratio (Price to Earnings) is -17.54 and Price to Sales (PS) ratio is 164.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FUSN PE ratio will change depending on the future growth rate expectations of investors.